10-Q quarterly report · filed Nov 10, 2026

Upstream Bio, Inc. (UPB) Q3 2026 10-Q Quarterly Report

Short answer

Upstream Bio, Inc. (UPB) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $395,000 (down 42.2% year over year) with net income of −$41M.

Q3 2026 key financials · XBRL

Revenue
$395,000
−42.2% YoY · −48.9% QoQ
Net income
−$41M
−22.1% YoY · −3.8% QoQ
Operating margin
-10982.0%
EPS (diluted)
−$0.76
−20.6% YoY · −5.6% QoQ

Source: XBRL data from the Upstream Bio, Inc. (UPB) Q3 2026 10-Q on SEC EDGAR. USD.

Upstream Bio, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $0.4M, down $0.3M YoY from $0.7M
  • Net loss $41.2M vs $33.7M YoY, operating loss $43.4M vs $37.8M
  • CRSwNP costs $3.5M, up $1.7M, best growth; COPD costs $9.0M, down $0.7M
  • Operating cash use $137.7M vs $102.6M YoY, investing provided $80.3M
  • Cash, equivalents and short-term investments $207.4M, funding expected through 2027; Phase 3 dosing planned Q1 2027

Risk Factors

  • New capital-raising risk: ATM Program permits up to $150.0 million, creating potential stockholder dilution
  • Financial runway: $207.4 million cash, cash equivalents and short-term investments expected to fund operations through 2027
  • New regulatory risk: FDA revised June 2026 guidance retains discretion to require additional clinical data, including a second trial
  • New privacy compliance risk: NIS 2 violations may trigger fines up to the greater of €10 million or 2% of worldwide annual turnover
  • Near-term development risk: Phase 2 CRSwNP and severe-asthma results may not translate to planned Phase 3 trials due to untested dosing regimens

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Upstream Bio, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.